Recurrent gene fusions in prostate cancer
US9938582B2 · kind B2 · utility
0Cited by
54References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2010 |
| Grant date | Apr 10, 2018 |
| Priority date | — |
| Expiry date | Jun 25, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.